Submission of outcome of board meeting.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astal Laboratories' board, meeting on 14 January 2026, approved two major preferential allotments to non-promoters. First, 3,04,25,632 equity shares at Rs. 91 per share (face value Rs. 10, premium Rs. 81) were allotted to 134 allottees who are shareholders of Sriven Pharmachem India Pvt Ltd, as consideration other than cash for acquiring 100% of that company, making it a wholly owned subsidiary. Second, 10,20,000 equity shares at Rs. 40 each (face value Rs. 10, premium Rs. 30) were allotted upon conversion of warrants held by 9 non-promoter investors, bringing in Rs. 3.06 crore in cash. As a result, the company's paid-up equity capital jumped from Rs. 1.02 crore to Rs. 42.22 crore, increasing the total share count from about 10.2 lakh to over 4.22 crore shares.
Existing shareholders face massive equity dilution — share count has expanded roughly 40x through these allotments, which could weigh on the stock price. However, the share-swap acquisition of Sriven Pharmachem could be value-accretive if the target has strong earnings, and the warrant conversion brings in fresh cash. Investors should watch for further disclosures on Sriven Pharmachem's financials and business fit.